TKTakahiro Kameda

Takahiro Kameda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takahiro Kameda has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ryunosuke Ohkawa

    Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan

    3 shared publications
  • Akira Yoshimoto

    Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU) Tokyo Japan

    2 shared publications
  • Shuji Tohda

    Clinical Laboratory, Institute of Science Tokyo Hospital, Tokyo, Japan

    2 shared publications
  • Akira Yoshimoto

    Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan

    1 shared publication
  • Azusa Yamazaki

    Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan; Clinical Laboratory, Institute of Science Tokyo Hospital, Tokyo, Japan

    1 shared publication
  • Azusa Yamazaki

    Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    1 shared publication

Latest Publications

  • Open Access

    High lipoprotein(a) results in overestimation of BQ-based low-density lipoprotein-cholesterol measurement

    by Azusa Yamazaki, Yuna Hakii, Masumi Ai, Shuji Miyake, Junichiro Takahashi, Akira Yoshimoto, Takahiro Kameda, Naoya Ichimura, Shuji Tohda, Shinji Yokoyama, et al.

  • Open Access

    Usefulness of plasma and apolipoprotein B-depleted serum samples in paraoxonase 1 assessment

    by Rina Kawaguchi, Akira Yoshimoto, Takahiro Kameda, Ryunosuke Ohkawa

  • Open Access

    Development and validation of direct assay for cholesterol content of erythrocytes

    by Azusa Yamazaki, Yuna Hakii, Akira Yoshimoto, Takahiro Kameda, Naoya Ichimura, Shuji Tohda, Ryunosuke Ohkawa

    Erythrocytes contain a significant amount of membrane cholesterol, which is continuously exchanged with lipoproteins. Recent studies suggest that erythrocyte cholesterol content correlates positively with atherosclerotic cardiovascular disease (ASCVD) severity independent of low-density lipoprotein levels, potentially reflecting residual ASCVD risk. However, conventional methods for measuring erythrocyte cholesterol content require labor-intensive lipid extraction procedures, limiting their clinical applicability. In this study, we developed a novel enzymatic assay that enables direct quantification of erythrocyte total cholesterol content using two denaturants to eliminate hemoglobin interference. This simple method demonstrated high accuracy and precision, as confirmed by intra-assay repeatability, between-day precision, linearity, and spike-recovery tests. Using this assay, we determined the erythrocyte cholesterol content per volume (154.8 ± 2.9 mg/dl in men, 155.9 ± 6.9 mg/dl in women) and per cell (139.0 ± 5.2 fg/cell in men, 140.8 ± 5.3 fg/cell in women) (n = 12, healthy subjects). While erythrocyte cholesterol content per volume correlated with the conventional method, the erythrocyte cholesterol content per cell showed no such correlation. Moreover, neither measure was associated with serum lipid levels, suggesting their potential as independent biomarkers for ASCVD. Additionally, we evaluated erythrocyte cholesterol content across different maturation stages and found that older erythrocytes had significantly lower cholesterol content, consistent with mass spectrometry results. These findings further validated the physiological relevance of the proposed method. In conclusion, we successfully established a simple and clinically applicable enzymatic method for measuring erythrocyte cholesterol content, providing novel insights into erythrocyte cholesterol metabolism and its potential role in ASCVD risk assessment.